

Classified Ads

PRINT ADVERTISING

THE EFFECTIVE WAY TO:

GROW YOUR WORKFORCE

INVEST IN YOUR FUTURE WITH FELLOWSHIPS

FURTHER YOUR EDUCATION WITH CME COURSES

PROMOTE AN UPCOMING CONFERENCE

These plus more opportunities available when you contact

Rhonda Truitt

rhonda.truitt@wt-group.com

443-512-8899 x 106

Kidney News Classified Advertising Information

Classified space is for advertising positions available, open faculty positions, course announcements, seminars, meetings and educational courses.

Display Advertising Rates

Ad Size	1x	3x
Full Page	\$2,525	\$2,345
1/2 Page	\$1,665	\$1,485
1/3 Page	\$1,435	\$1,375
1/4 Page	\$1,205	\$1,090
1/6 Page	\$1,035	\$1,025

Line Advertising Rates

Please contact for rate information

Closing Date & Cancellations:

Copy must be received four weeks in advance of the month in which the ad is to appear. Cancellation requests must be made in written form by fax, e-mail or postal mail and will be honored for the earliest applicable issue.

**ALL ADS
MUST BE PREPAID**

Contact:

Rhonda Truitt
rhonda.truitt@wt-group.com
P: 443-512-8899 x. 106 F: 443-512-8909

Industry Spotlight

Dialysate Concentrate Recalled


In July 2015, Fresenius issued a voluntary recall of more than 1.8 million 6.4-L bottles of NaturaLyte Liquid Bicarbonate Concentrate (see FDA website for details about the recalled units). The concentrate is formulated for use with a three-stream hemodialysis machine that is calibrated for acid and bicarbonate concentrates, the FDA noted.

NaturaLyte is also making news on some legal websites for a class-action suit against the manufacturer, alleging that the product, along with a different Fresenius dialysate product called GranuFlo, contributed to harmful and/or fatal side effects such as cardiac arrhythmia and low blood pressure. On July 1, 2015, the latest case was filed in Mississippi. The case joins other cases included in previously established multidistrict

litigation (MDL No. 2428, In Re: Fresenius GranuFlo/Naturalyte Dialysate Products Liability Litigation), created to expedite trials for related lawsuits.

The New York Times reported in 2012 about questions regarding Fresenius failure to warn non-Fresenius dialysis clinics about possible adverse cardiac events with GranuFlo use. The events might be brought on during dialysis related to a build-up of bicarbonate in patients, the *Times* reported. Clinics began to monitor blood levels for problems, and the product was relabeled.

In June, Fresenius Medical Care Renal Therapies Group began a voluntary recall of Crit-Line blood chambers used in hemodialysis because of product leakage problems. The recall involved 22.6 million



products sold in the United States, Ireland, Spain, Slovenia, Great Britain, the Netherlands, Norway, Mexico, Egypt, and the Czech Republic. ●

Index to Advertisers

CryoLife	Back Page
Otsuka	Page 2-3